Diabetic Retinopathy/Diabetic Macular Edema (DR/DME) - Payer Implications Fact Sheet

Release Date: June 30, 2024 Expiration Date: December 31, 2025 Estimated Time to Complete Activity: 0.5 hour Compatible with all modern browsers and mobile devices

Target Audience

This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview

While the choice of treatment for diabetic retinopathy/diabetic macular edema (DR/DME) is largely based on the experience and preference of the treating retinal specialist and patient preferences, payers are key stakeholders in impacting treatment selection through formulary placement, step therapy, and site-of-care policies which can affect member access. Payers continue to need the latest updates on DR/DME to apply health plan best practices and improve management and outcomes.

Educational Objectives 
After completing this activity, the participant should be better able to:

• Describe the clinical and economic burden of DR/DME, including the cost of untreated disease
• Characterize pharmacologic treatment options for DR/DME in terms of efficacy, safety, and dosing intervals
• Examine medical and pharmacy benefit design strategies that facilitate appropriate evidence-based treatment for DR/DME
• Identify current disparities in the care of retinal diseases and means by which to address the impact of SDOH via utilization management programs

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources, Inc., and Impact Education, LLC. Medical Education Resources is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0003680-9999-24-163-H01-P
Type of Activity: Knowledge-based

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
Medical Education Resources designates this enduring activity for a maximum of 0.5 ANCC nursing contact hour. Nurses will be awarded contact hours upon successful completion of the activity.

Disclosure of Relevant Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The MER planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.